ibrutinib + acalabrutinib

Ibrutinib + acalabrutinib is an off-label combination of two covalent small-molecule Bruton tyrosine kinase (BTK) inhibitors, generally considered a non-standard and pharmacologically redundant regimen rather than a distinct commercial product. Ibrutinib is a first-generation BTK inhibitor that irreversibly binds Cys481 in BTK but also inhibits several other kinases (for example SRC-family kinases and interleukin-2–inducible T-cell kinase), contributing to broader immunomodulatory and cardiovascular toxicities.[4][12] Acalabrutinib is a second-generation BTK inhibitor rationally designed to bind the same Cys481 residue with improved selectivity for BTK, resulting in similar inhibition of B-cell receptor signaling and antileukemic activity in chronic lymphocytic leukemia (CLL) with reduced off-target kinase inhibition and a more favorable safety profile compared with ibrutinib.[2][4][6] The two agents are typically evaluated as alternatives rather than in combination, including in head‑to‑head trials in relapsed CLL, because co-administration would be expected primarily to increase BTK occupancy and overlapping toxicity without a clearly established therapeutic advantage.[4][5][11]